The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.66 billion in 2025 to $3.87 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to early diagnosis of bladder cancer, reliance on transurethral resection, limited adoption of intravesical therapy, growth in hospital pharmacy infrastructure, low awareness of nmibc staging.
The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising prevalence of bladder cancer, increasing adoption of immunotherapy and chemotherapy, growth in online and retail pharmacy channels, expanding use of advanced diagnostic imaging, advancing personalized treatment approaches. Major trends in the forecast period include rising adoption of ai-powered diagnostic tools, increasing use of genomics and precision medicine approaches, growing implementation of data-driven clinical decision support, expanding deployment of minimally invasive therapeutic techniques, advancing integration of connected health monitoring solutions.
The growing emphasis on personalized medicine is expected to drive the growth of the non-muscle invasive bladder cancer (NMIBC) market in the coming years. Personalized medicine tailors medical treatment to an individual’s genetic profile, lifestyle, and environment to achieve more effective outcomes. This focus is being fueled by advancements in genomic research, enhanced diagnostic tools, and increasing demand for targeted therapies. NMIBC supports personalized medicine by enabling treatment plans customized to specific tumor characteristics, genetic markers, and patient profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a U.S.-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the emphasis on personalized medicine is driving the growth of the NMIBC market.
Major companies in the NMIBC market are developing innovative solutions such as immunotherapies to improve patient outcomes. Immunotherapy leverages the body’s immune system to recognize and destroy cancer cells by enhancing immune responses. For example, in March 2024, ImmunityBio Inc., a U.S.-based biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive NMIBC featuring carcinoma in situ (CIS), with or without papillary tumors. Clinical trials showed that ANKTIVA, used alongside Bacillus Calmette-Guérin (BCG), provides an effective option for patients unresponsive to standard BCG therapy. ANKTIVA is an IL-15 agonist immunotherapy that stimulates natural killer (NK) cells and CD8+ killer T cells to target and eliminate cancer cells.
In April 2024, Ferring Pharmaceuticals, a Switzerland-based biopharmaceutical company, partnered with SK Pharmteco to support the production of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy for high-risk BCG-unresponsive NMIBC. This collaboration aims to expand manufacturing capacity and ensure a consistent global supply of the therapy. SK Pharmteco is a U.S.-based contract development and manufacturing organization.
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co Inc, AstraZeneca plc, Astellas Pharma US Inc, EMD Serono Inc, Genentech Inc, Aura Biosciences Inc, UroGen Pharma Ltd, Protara Therapeutics Inc, Istari Oncology Inc, Heat Biologics Inc, Viventia Bio Inc, ImmunityBio Inc, Altor BioScience Corporation, SURGE Therapeutics Inc, Pfizer Inc, Hoffmann‑La Roche Ltd, CG Oncology Inc, Tyra Biosciences Inc, Prokarium Ltd, ImmVira Pharma Co Ltd, Trigone Pharma Ltd, enGene Holdings Inc, Atonco Pharma Ltd.
North America was the largest region in the non-muscle invasive bladder cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the non-muscle invasive bladder cancer market by increasing costs of imported therapeutic agents, surgical equipment, and diagnostic instruments. Segments including immunotherapy, chemotherapy, and intravesical therapy are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs raise procurement expenses and lead times, they also encourage local manufacturing, drive development of cost-effective treatment solutions, and strengthen domestic healthcare supply chains.
The non-muscle invasive bladder cancer market research report is one of a series of new reports that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer that is limited to the inner layers of the bladder wall and has not invaded the muscle layer. It is usually diagnosed at an early stage and can often be effectively treated using methods such as transurethral resection, intravesical therapy, or careful surveillance.
The primary stages in the non-muscle invasive bladder cancer market include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ is a form of NMIBC in which abnormal cells are present in the bladder lining but have not penetrated deeper tissues. Treatment options include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, targeting various tumors such as low-grade and high-grade tumors. End users include hospital pharmacies, retail pharmacies, and online pharmacies.
The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising prevalence of bladder cancer, increasing adoption of immunotherapy and chemotherapy, growth in online and retail pharmacy channels, expanding use of advanced diagnostic imaging, advancing personalized treatment approaches. Major trends in the forecast period include rising adoption of ai-powered diagnostic tools, increasing use of genomics and precision medicine approaches, growing implementation of data-driven clinical decision support, expanding deployment of minimally invasive therapeutic techniques, advancing integration of connected health monitoring solutions.
The growing emphasis on personalized medicine is expected to drive the growth of the non-muscle invasive bladder cancer (NMIBC) market in the coming years. Personalized medicine tailors medical treatment to an individual’s genetic profile, lifestyle, and environment to achieve more effective outcomes. This focus is being fueled by advancements in genomic research, enhanced diagnostic tools, and increasing demand for targeted therapies. NMIBC supports personalized medicine by enabling treatment plans customized to specific tumor characteristics, genetic markers, and patient profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a U.S.-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the emphasis on personalized medicine is driving the growth of the NMIBC market.
Major companies in the NMIBC market are developing innovative solutions such as immunotherapies to improve patient outcomes. Immunotherapy leverages the body’s immune system to recognize and destroy cancer cells by enhancing immune responses. For example, in March 2024, ImmunityBio Inc., a U.S.-based biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive NMIBC featuring carcinoma in situ (CIS), with or without papillary tumors. Clinical trials showed that ANKTIVA, used alongside Bacillus Calmette-Guérin (BCG), provides an effective option for patients unresponsive to standard BCG therapy. ANKTIVA is an IL-15 agonist immunotherapy that stimulates natural killer (NK) cells and CD8+ killer T cells to target and eliminate cancer cells.
In April 2024, Ferring Pharmaceuticals, a Switzerland-based biopharmaceutical company, partnered with SK Pharmteco to support the production of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy for high-risk BCG-unresponsive NMIBC. This collaboration aims to expand manufacturing capacity and ensure a consistent global supply of the therapy. SK Pharmteco is a U.S.-based contract development and manufacturing organization.
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co Inc, AstraZeneca plc, Astellas Pharma US Inc, EMD Serono Inc, Genentech Inc, Aura Biosciences Inc, UroGen Pharma Ltd, Protara Therapeutics Inc, Istari Oncology Inc, Heat Biologics Inc, Viventia Bio Inc, ImmunityBio Inc, Altor BioScience Corporation, SURGE Therapeutics Inc, Pfizer Inc, Hoffmann‑La Roche Ltd, CG Oncology Inc, Tyra Biosciences Inc, Prokarium Ltd, ImmVira Pharma Co Ltd, Trigone Pharma Ltd, enGene Holdings Inc, Atonco Pharma Ltd.
North America was the largest region in the non-muscle invasive bladder cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the non-muscle invasive bladder cancer market by increasing costs of imported therapeutic agents, surgical equipment, and diagnostic instruments. Segments including immunotherapy, chemotherapy, and intravesical therapy are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs raise procurement expenses and lead times, they also encourage local manufacturing, drive development of cost-effective treatment solutions, and strengthen domestic healthcare supply chains.
The non-muscle invasive bladder cancer market research report is one of a series of new reports that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer that is limited to the inner layers of the bladder wall and has not invaded the muscle layer. It is usually diagnosed at an early stage and can often be effectively treated using methods such as transurethral resection, intravesical therapy, or careful surveillance.
The primary stages in the non-muscle invasive bladder cancer market include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ is a form of NMIBC in which abnormal cells are present in the bladder lining but have not penetrated deeper tissues. Treatment options include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, targeting various tumors such as low-grade and high-grade tumors. End users include hospital pharmacies, retail pharmacies, and online pharmacies.
The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-Muscle Invasive Bladder Cancer Market Characteristics
3. Non-Muscle Invasive Bladder Cancer Market Supply Chain Analysis
4. Global Non-Muscle Invasive Bladder Cancer Market Trends and Strategies
5. Non-Muscle Invasive Bladder Cancer Market Analysis of End Use Industries
7. Global Non-Muscle Invasive Bladder Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Non-Muscle Invasive Bladder Cancer Total Addressable Market (TAM) Analysis for the Market
9. Non-Muscle Invasive Bladder Cancer Market Segmentation
10. Non-Muscle Invasive Bladder Cancer Market Regional and Country Analysis
11. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market
12. China Non-Muscle Invasive Bladder Cancer Market
13. India Non-Muscle Invasive Bladder Cancer Market
14. Japan Non-Muscle Invasive Bladder Cancer Market
15. Australia Non-Muscle Invasive Bladder Cancer Market
16. Indonesia Non-Muscle Invasive Bladder Cancer Market
17. South Korea Non-Muscle Invasive Bladder Cancer Market
18. Taiwan Non-Muscle Invasive Bladder Cancer Market
19. South East Asia Non-Muscle Invasive Bladder Cancer Market
20. Western Europe Non-Muscle Invasive Bladder Cancer Market
21. UK Non-Muscle Invasive Bladder Cancer Market
22. Germany Non-Muscle Invasive Bladder Cancer Market
23. France Non-Muscle Invasive Bladder Cancer Market
24. Italy Non-Muscle Invasive Bladder Cancer Market
25. Spain Non-Muscle Invasive Bladder Cancer Market
26. Eastern Europe Non-Muscle Invasive Bladder Cancer Market
27. Russia Non-Muscle Invasive Bladder Cancer Market
28. North America Non-Muscle Invasive Bladder Cancer Market
29. USA Non-Muscle Invasive Bladder Cancer Market
30. Canada Non-Muscle Invasive Bladder Cancer Market
31. South America Non-Muscle Invasive Bladder Cancer Market
32. Brazil Non-Muscle Invasive Bladder Cancer Market
33. Middle East Non-Muscle Invasive Bladder Cancer Market
34. Africa Non-Muscle Invasive Bladder Cancer Market
36. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape and Company Profiles
37. Non-Muscle Invasive Bladder Cancer Market Other Major and Innovative Companies
40. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Non-Muscle Invasive Bladder Cancer Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-muscle invasive bladder cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-muscle invasive bladder cancer? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-muscle invasive bladder cancer market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Stage: Carcinoma In Situ (CIS); T1 Stage; Ta Stage2) By Treatment: Immunotherapy; Chemotherapy; Surgery; Intravesical Therapy; Other Treatments
3) By Tumor: Low-Grade Tumours; High-Grade Tumours
4) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS; Low-Grade CIS2) By T1 Stage: T1a Stage (Superficial Tumors); T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage; High-Grade Ta Stage
Companies Mentioned: Johnson & Johnson; Janssen Research & Development LLC; Merck & Co Inc; AstraZeneca plc; Astellas Pharma US Inc; EMD Serono Inc; Genentech Inc; Aura Biosciences Inc; UroGen Pharma Ltd; Protara Therapeutics Inc; Istari Oncology Inc; Heat Biologics Inc; Viventia Bio Inc; ImmunityBio Inc; Altor BioScience Corporation; SURGE Therapeutics Inc; Pfizer Inc; Hoffmann‑La Roche Ltd; CG Oncology Inc; Tyra Biosciences Inc; Prokarium Ltd; ImmVira Pharma Co Ltd; Trigone Pharma Ltd; enGene Holdings Inc; Atonco Pharma Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Non-Muscle Invasive Bladder Cancer market report include:- Johnson & Johnson
- Janssen Research & Development LLC
- Merck & Co Inc
- AstraZeneca plc
- Astellas Pharma US Inc
- EMD Serono Inc
- Genentech Inc
- Aura Biosciences Inc
- UroGen Pharma Ltd
- Protara Therapeutics Inc
- Istari Oncology Inc
- Heat Biologics Inc
- Viventia Bio Inc
- ImmunityBio Inc
- Altor BioScience Corporation
- SURGE Therapeutics Inc
- Pfizer Inc
- Hoffmann‑La Roche Ltd
- CG Oncology Inc
- Tyra Biosciences Inc
- Prokarium Ltd
- ImmVira Pharma Co Ltd
- Trigone Pharma Ltd
- enGene Holdings Inc
- Atonco Pharma Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.87 Billion |
| Forecasted Market Value ( USD | $ 4.82 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
